Profound Medical Corp. (PROF)
2025-06-30 | 2025-03-31 | |||
|---|---|---|---|---|
| Revenue (note 11) | 2,211 | 2,621 | ||
| Cost of sales | 593 | 768 | ||
| Gross profit | 1,618 | 1,853 | ||
| Selling, general and administrative | 9,326 | 8,211 | ||
| Research and development | 6,098 | 4,808 | ||
| Total operating expenses | 15,424 | 13,019 | ||
| Operating loss | -13,806 | -11,166 | ||
| Net finance (income) expense | 343 | 445 | ||
| Net foreign exchange (gain) loss | -2,168 | 38 | ||
| Total other (income) expenses | -1,825 | 483 | ||
| Net loss before income taxes | -15,631 | -10,683 | ||
| Deferred tax recovery | -14 | - | ||
| Income tax expense | 78 | 41 | ||
| Total income tax expense | 64 | 41 | ||
| Net loss attributed to shareholders for the period | -15,695 | -10,724 | ||
| Foreign currency translation adjustment | 2,713 | 103 | ||
| Net loss and other comprehensive loss for the period | -12,982 | -10,621 | ||
| Earnings per share, basic | 0.52 | 0.36 | ||
| Earnings per share, diluted | 0.52 | 0.36 | ||
| Weighted average number of shares outstanding, basic | 30,053,142 | 30,041,735 | ||
| Weighted average number of shares outstanding, diluted | 30,053,142 | 30,041,735 | ||